
What future research directions, follow-up studies, or next steps does this paper suggest? Extract proposed experiments, identified knowledge gaps, and recommended investigations. Include reasoning about research priorities and feasibility within your answer. Provide APA-style reference.

**Example Output:**
```json
{
  "pairs": [
    {
      "question": "What Phase II clinical trials are recommended as next steps?",
      "answer": "**Immediate Next Steps (6-12 months):**\n- **Dose Optimization Study:** Systematic evaluation of 5 dose levels (0.1, 0.5, 1.0, 2.0, 5.0 mg/kg) to establish optimal therapeutic window and minimize side effects\n- **Mechanism Validation:** CRISPR knockout studies targeting proposed pathway components (PKC-δ, mTOR, AMPK) to confirm causal relationships\n- **Biomarker Development:** Validation of 12 identified protein biomarkers in independent cohort (n=200) for predicting treatment response\n\n**Short-term Studies (1-2 years):**\n- **Multi-center Clinical Trial:** Phase II randomized controlled trial across 8 centers with 400 patients to confirm efficacy and safety signals\n- **Companion Diagnostic:** Development of point-of-care assay for predictive biomarkers to enable personalized treatment selection\n- **Combination Therapy:** Testing synergistic effects with standard-of-care treatments using factorial design (2×2×2 matrix)\n- **Pharmacovigilance:** Long-term safety monitoring with 5-year follow-up to detect rare adverse events\n\n**Medium-term Research (3-5 years):**\n- **Pediatric Studies:** Age-appropriate formulation development and safety/efficacy testing in children 6-17 years old\n- **Resistance Mechanisms:** Investigation of acquired resistance patterns through serial tumor sampling and genomic analysis\n- **Delivery Optimization:** Nanoparticle formulations to improve tissue penetration and reduce systemic exposure\n- **Artificial Intelligence:** Machine learning algorithms to predict individual patient responses using multi-omics data\n\n**Long-term Vision (5-10 years):**\n- **Prevention Studies:** Primary prevention trials in high-risk populations identified through genetic screening\n- **Global Health Applications:** Adapted formulations for resource-limited settings with simplified cold-chain requirements\n- **Next-generation Compounds:** Structure-activity relationship studies to develop more potent and selective analogs\n\n**Knowledge Gaps to Address:**\n- **Pharmacokinetics:** Limited data on CNS penetration and brain-blood barrier transport mechanisms\n- **Drug Interactions:** Potential interactions with 47 commonly prescribed medications remain unexplored\n- **Special Populations:** Safety and efficacy unknown in pregnancy, hepatic impairment, and elderly patients\n- **Biomarker Dynamics:** Temporal changes in biomarker expression during treatment need characterization\n\n**Technical Challenges:**\n- **Analytical Methods:** Current LC-MS assay requires improvement for routine clinical use (current LOQ: 0.5 ng/mL, target: 0.05 ng/mL)\n- **Manufacturing Scale-up:** Synthesis route needs optimization for large-scale production while maintaining quality\n- **Stability Issues:** Formulation shows 15% degradation at room temperature after 6 months, requiring improved excipients\n\n**Reasoning:** The dose optimization study is prioritized because current single-dose data provides insufficient information for clinical development - the therapeutic window may be narrow given the mechanism of action. Mechanism validation through genetic approaches will strengthen patent applications and address regulatory requirements for target engagement proof. The multi-center trial design addresses limitations of the current single-center study while providing data for regulatory submission. Biomarker development is critical for commercial success, as personalized medicine approaches typically achieve better market penetration. Pediatric studies are planned after adult safety is established, following FDA guidance for age de-escalation. The resistance mechanism studies are essential because similar pathway-targeted drugs have shown acquired resistance within 12-18 months. Long-term prevention studies represent the highest potential impact but require substantial investment and time - they're positioned as stretch goals contingent on early-stage success.",
      "reference": "Thompson, D., Lee, H., & Patel, M. (2024). Translational roadmap for novel therapeutic agents: From discovery to clinical implementation. *Nature Reviews Drug Discovery*, 23(5), 378-394. https://doi.org/10.1038/s41573-024-00892-1"
    },
    {
      "question": "What Phase II clinical trials are recommended as next steps?",
      "answer": "**Immediate Next Steps (6-12 months):**\n- **Dose Optimization Study:** Systematic evaluation of 5 dose levels (0.1, 0.5, 1.0, 2.0, 5.0 mg/kg) to establish optimal therapeutic window and minimize side effects\n- **Mechanism Validation:** CRISPR knockout studies targeting proposed pathway components (PKC-δ, mTOR, AMPK) to confirm causal relationships\n- **Biomarker Development:** Validation of 12 identified protein biomarkers in independent cohort (n=200) for predicting treatment response\n\n**Short-term Studies (1-2 years):**\n- **Multi-center Clinical Trial:** Phase II randomized controlled trial across 8 centers with 400 patients to confirm efficacy and safety signals\n- **Companion Diagnostic:** Development of point-of-care assay for predictive biomarkers to enable personalized treatment selection\n- **Combination Therapy:** Testing synergistic effects with standard-of-care treatments using factorial design (2×2×2 matrix)\n- **Pharmacovigilance:** Long-term safety monitoring with 5-year follow-up to detect rare adverse events\n\n**Medium-term Research (3-5 years):**\n- **Pediatric Studies:** Age-appropriate formulation development and safety/efficacy testing in children 6-17 years old\n- **Resistance Mechanisms:** Investigation of acquired resistance patterns through serial tumor sampling and genomic analysis\n- **Delivery Optimization:** Nanoparticle formulations to improve tissue penetration and reduce systemic exposure\n- **Artificial Intelligence:** Machine learning algorithms to predict individual patient responses using multi-omics data\n\n**Long-term Vision (5-10 years):**\n- **Prevention Studies:** Primary prevention trials in high-risk populations identified through genetic screening\n- **Global Health Applications:** Adapted formulations for resource-limited settings with simplified cold-chain requirements\n- **Next-generation Compounds:** Structure-activity relationship studies to develop more potent and selective analogs\n\n**Knowledge Gaps to Address:**\n- **Pharmacokinetics:** Limited data on CNS penetration and brain-blood barrier transport mechanisms\n- **Drug Interactions:** Potential interactions with 47 commonly prescribed medications remain unexplored\n- **Special Populations:** Safety and efficacy unknown in pregnancy, hepatic impairment, and elderly patients\n- **Biomarker Dynamics:** Temporal changes in biomarker expression during treatment need characterization\n\n**Technical Challenges:**\n- **Analytical Methods:** Current LC-MS assay requires improvement for routine clinical use (current LOQ: 0.5 ng/mL, target: 0.05 ng/mL)\n- **Manufacturing Scale-up:** Synthesis route needs optimization for large-scale production while maintaining quality\n- **Stability Issues:** Formulation shows 15% degradation at room temperature after 6 months, requiring improved excipients\n\n**Reasoning:** The dose optimization study is prioritized because current single-dose data provides insufficient information for clinical development - the therapeutic window may be narrow given the mechanism of action. Mechanism validation through genetic approaches will strengthen patent applications and address regulatory requirements for target engagement proof. The multi-center trial design addresses limitations of the current single-center study while providing data for regulatory submission. Biomarker development is critical for commercial success, as personalized medicine approaches typically achieve better market penetration. Pediatric studies are planned after adult safety is established, following FDA guidance for age de-escalation. The resistance mechanism studies are essential because similar pathway-targeted drugs have shown acquired resistance within 12-18 months. Long-term prevention studies represent the highest potential impact but require substantial investment and time - they're positioned as stretch goals contingent on early-stage success.",
      "reference": "Thompson, D., Lee, H., & Patel, M. (2024). Translational roadmap for novel therapeutic agents: From discovery to clinical implementation. *Nature Reviews Drug Discovery*, 23(5), 378-394. https://doi.org/10.1038/s41573-024-00892-1"
    }
  ]
}
```

Output as many pairs of question/answer/reference as needed to summarize the content. 
The output must be pure JSON without any markdown fencing.  Escape any special characters using JSON appropriate escaping.
The output must be JSON only.  Do not include any additional information of any kind.
Don't nest JSON inside the question, answer or reference attributes.
Replace any non-ASCII or special characters with LaTeX (preferred) or simple text equivalent.
You must properly escape any markdown characters that are not allowed in raw JSON.  If you are outputting LaTeX, ensure the backslashes are escaped as double backslashes.